Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any - 2 |
| Updated: | 5/19/2016 |
| Start Date: | July 2010 |
| End Date: | May 2016 |
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
This research study is studying lestaurtinib with or with chemotherapy in samples from young
patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in
cell samples from patients with cancer in the laboratory may help doctors learn more about
the effects of this treatment on cancer cells. It may also help doctors identify biomarkers
related to cancer.
patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in
cell samples from patients with cancer in the laboratory may help doctors learn more about
the effects of this treatment on cancer cells. It may also help doctors identify biomarkers
related to cancer.
PRIMARY OBJECTIVES:
I. Determine the potential of lestaurtinib with or without chemotherapy agents in treating
samples from infants with leukemia.
II. Determine whether FLT3 protein expression level and/or activation and sensitivity to
lestaurtinib differ between subgroups of infants with leukemia.
III. Determine whether lestaurtinib activates STAT5, AKT, and RAS-MAPK and other pathways.
IV. Determine whether lestaurtinib can synergize with other chemotherapy agents kill infant
leukemia cells.
OUTLINE: This is a multicenter study.
Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy
agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to
lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK
and other pathways by western blot. The most effective treatment from this study is then
validated in vivo in a NOD/SCID xenograft model.
I. Determine the potential of lestaurtinib with or without chemotherapy agents in treating
samples from infants with leukemia.
II. Determine whether FLT3 protein expression level and/or activation and sensitivity to
lestaurtinib differ between subgroups of infants with leukemia.
III. Determine whether lestaurtinib activates STAT5, AKT, and RAS-MAPK and other pathways.
IV. Determine whether lestaurtinib can synergize with other chemotherapy agents kill infant
leukemia cells.
OUTLINE: This is a multicenter study.
Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy
agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to
lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK
and other pathways by western blot. The most effective treatment from this study is then
validated in vivo in a NOD/SCID xenograft model.
Inclusion Criteria:
- Cryopreserved samples from infants with leukemia available
We found this trial at
1
site
Monrovia, California 91016
Principal Investigator: Patrick A. Brown, MD
Phone: 410-614-4915
Click here to add this to my saved trials
